| 830 |
Ni-kshay Poshan Yojana [NPY] |
18/10/2024 |
Community engagement and call centre |
| 86 |
National TB Elimination Program [NTEP] |
18/10/2024 |
Training and HR Development |
| 6802 |
Roles and Responsibility of ASHA/Community Volunteers in 100 Days Campaign |
18/10/2024 |
|
| 6803 |
Key Strategies of the 100 Days Campaign |
18/10/2024 |
|
| 6805 |
Roles and Responsibilities of STS/TBHVs under the 100 Days Campaign |
18/10/2024 |
|
| 6807 |
Roles and Responsibilities of ASHAs/CVs under the 100 Days Campaign |
18/10/2024 |
|
| 6808 |
Activities to be Undertaken by ASHAs/CVs- Line Listing |
18/10/2024 |
|
| 6809 |
Activities to be Undertaken by ASHAs/CVs- Screening and Testing |
18/10/2024 |
|
| 6810 |
Activities to be Undertaken by ASHAs/CVs- Initiating TB Treatment |
18/10/2024 |
|
| 6811 |
Activities to be Undertaken by ASHAs/CVs- Home Visits |
18/10/2024 |
|
| 6812 |
Activities to be Undertaken by ASHAs/CVs- Extending Treatment Support |
18/10/2024 |
|
| 6813 |
Activities to be Undertaken by ASHAs/CVs- Support TPT |
18/10/2024 |
|
| 6814 |
Activities to be Undertaken by ASHAs/CVs- Community Awareness |
18/10/2024 |
|
| 6815 |
Preparation for the 100 Days Campaign- Community Team and Campaign Kit |
18/10/2024 |
|
| 6816 |
Incentives for ASHAs/CVs under the 100 Days Campaign |
18/10/2024 |
|
| 6801 |
Roles and Responsibilities of MO-PHI under the 100 Days Campaign |
18/10/2024 |
|
| 6800 |
Introduction to 100 Days Campaign |
18/10/2024 |
|
| 6804 |
Roles and Responsibilities of CHO under the 100 Days Campaign |
18/10/2024 |
|
| 6820 |
Preparation for the 100 Days Campaign- Team Members |
18/10/2024 |
|
| 861 |
System for TB Elimination in Private Sector [STEPS] |
20/10/2024 |
Partnerships and Multisectoral Engagement |
| 862 |
Patient Provider Support Agency [PPSA] |
20/10/2024 |
Partnerships and Multisectoral Engagement |
| 5 |
Advocacy Communication and Social Mobilisation [ACSM] |
20/10/2024 |
Advocacy communication and social mobilization |
| 1088 |
Methods for Pharmacovigilance Activity Reporting |
20/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1317 |
Universal Drug-susceptibility Testing [UDST] for TB |
20/10/2024 |
Laboratory services and management |
| 1416 |
Polymerase Chain Reaction [PCR] Technology for M.TB |
21/10/2024 |
Laboratory services and management |
| 1647 |
NTEP Performance Indicator - Percentage of TB Notified Patients with Universal Drug Susceptibility Testing [UDST] Done |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1653 |
NTEP Performance Indicator – Percentage Of Multidrug-resistant [MDR]/ Rifampicin-resistant [RR] Patients Initiated on Treatment Out of Totally Diagnosed |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1644 |
Root Cause Analysis [RCA] for Low Performance in Percentage of Target TB Notification Achieved |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1648 |
RCA for low performance of Percentage of TB Notified Cases with Universal Drug Susceptibility Testing Done |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1650 |
RCA for Low Performance - Suggested Solutions - Case Studies along 4 |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
